Prediction of fracture risk in postmenopausal type 2 diabetes mellitus with osteopenia by serum OPG, TGF-β and IL-6 levels

doi:10.3877/cma.j.issn.2096-0263.2018.01.003

Abstract

Abstract:

Objective

To evaluate the variations of serum OPG, TGF-β and IL-6 levels with bone loss in postmenopausal women with or without type 2 diabetes mellitus (T2DM), to elucidate the role of serum OPG, TGF-β and IL-6 levels in prediction for 10-year probability of fracture risk, and to explore the impact of serum OPG, TGF-β and IL-6 levels on the progression of type 2 diabetic fracture.

Methods

This study included 128 postmenopausal women who were diagnosed as osteopenia (areal bone mineral density at spine and hip of all subjects were measured by DXA, patients with T score more than -2.5 and less than -1.0 were diagnosed as osteopenea). They were divided into two groups, T2DM group and non-T2DM group. Besides of BMD, all subjects were measured the serum levels of OPG, TGF-β and IL-6. Furthermore, we predicted the 10-year probability of fracture risk in all cohorts by FRAX? and analyzed the correlations of the risk with serum levels of OPG, TGF-β and IL-6 in all subjects.

Results

There were no significant differences of BMD between the two groups (Z=0.841, P>0.05). However, the serum levels of OPG (Z=2.264, P=0.024), TGF-β (Z=2.836, P=0.005) and IL-6 (Z=2.431, P=0.015) in T2DM group were higher than that in non-T2DM group. Furthermore, the serum levels of OPG, TGF-β and IL-6 were correlated with the 10-year probability of fracture risk in T2DM group.

Conclusion

The serum levels of OPG, TGF-β and IL-6 increased in osteopenia patients with T2DM, suggesting that the increased inflammatory factors could be used as predictors for the 10-year probability of fracture risk in osteopenia patients with T2DM.

Key words: Diabetes mellitus, Type 2, Osteoporosis, Serum response factor, Fracture risk

Xiaoxue Bao, Na Wang, Yukun Li, Yan Wang, Peng Xue. Prediction of fracture risk in postmenopausal type 2 diabetes mellitus with osteopenia by serum OPG, TGF-β and IL-6 levels[J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2018, 04(01): 9-13.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlngkykfdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2096-0263.2018.01.003

https://zhlngkykfdzzz.cma-cmc.com.cn/EN/Y2018/V04/I01/9

Figures/Tables 3

References 23

1	刘君英, 阎德文, 邓建新, 等. 围绝经期2型糖尿病骨质疏松症治疗中胰岛素与阿仑膦酸钠的联合应用效果观察[J]. 山东医药, 2017, 57(19): 69-71.
2	Janas A, Folwarczna J. Opioid receptor agonists May favorably affect bone mechanical properties in rats with estrogen deficiency-induced osteoporosis [J]. Naunyn Schmiedebergs Arch Pharmacol, 2017, 390(2): 175-185.
3	Watanabe R, Okazaki R. Diabetes mellitus and osteoporosis. Diabetes mellitus and bone and Calcium metabolism [J]. Clin Calcium, 2012, 22(9): 1307-1314.
4	Montagnani A, Gonnelli S, Alessandri MA. Osteoporosis and risk of fracture in patients with diabetes: an update [J]. Aging Clin Exp Res, 2011, 23(2): 84-90.
5	Xiang GD, Xu L, Zhao LS, et al. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes [J]. Diabetes, 2006, 55(7): 2126-2131.
6	胡玲萍, 吴雪华. 老年男性2型糖尿病并发骨质疏松相关危险因素研究现状[J]. 中国临床保健杂志, 2014, 12(1): 107-109.
7	谢楚海, 陈斌伟, 郭剑鸿, 等. 阿法骨化醇与骨化三醇对骨质疏松患者HOP、BALP及组织形态学的影响[J]. 中国老年学杂志, 2015, 35(19): 5590-5591.
8	Hozayen WG, El-Desouky MA, Soliman HA, et al. Antiosteoporotic effect of Petroselinum crispum, Ocimum basilicum and Cichorium intybus L. in glucocorticoid-induced osteoporosis in rats [J]. BMC Complement Altern Med, 2016, 16(1): 165.
9	Shin YA, Lee KY. Low estrogen levels and obesity are associated with shorter telomere lengths in pre- and postmenopausal women [J]. J Exerc Rehabil, 2016, 12(3): 238-246.
10	Bellet M, Gray KP, Francis PA, et al. Twelve-Month estrogen levels in premenopausal women with hormone Receptor-Positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy [J]. J Clin Oncol, 2016, 34(14): 1584-1593.
11	叶任高, 陆再英. 内科学[M]. 第6版. 北京: 人民卫生出版社, 2015: 860-861.
12	Leslie WD, Lix LM, Johansson H, et al. Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration [J]. J Bone Miner Res, 2010, 25(11): 2350-2358.
13	Sornay-Rendu E, Munoz F, Delmas PD, et al. The FRAX tool in French women:how well does it describe the real incidence of fracture in the OFELY cohort [J]. J Bone Miner Res, 2010, 25(10): 2101-2107.
14	肖扬, 李强翔, 王万春, 等. 骨质疏松症和细胞因子关系的新思考[J]. 医学与哲学, 2006, 27(12): 60-62.
15	Lim J, Tu X, Choi K, et al. BMP-Smad4 signaling is required for precartilaginous mesenchymal condensation Independent of Sox9 in the mouse [J]. Dev Biol, 2015, 400(1): 132-138.
16	Zhou N, Li Q, Lin X, et al. BMP2 induces chondrogenic differentiation, osteogenic differentiation and endochondral ossification in stem cells [J]. Cell Tissue Res, 2016, 366(1): 101-111.
17	Karst M, Gorny G, GalvinRJ, et al. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGFβregulation of osteoclast differentiation [J]. J Cell Physiol, 2004, 200(1): 99.
18	Koseki T, Gao Y, Okahashi N, et al. Role of TGF-beta family in osteoclastogenesis induced by RANKL [J]. Cell Signal, 2002, 14(1): 31-36.
19	Tang Y, Wu X, Lei W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation [J]. Nat Med, 2009, 15(7): 757-765.
20	Yano K, Tsuda E, Washida N, et al. Inmmnological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis [J]. J Bone Miner Res, 1999, 14(4): 518-527.
21	朱明明. 2型糖尿病患者血清骨保护素水平与氧化应激的关系[J]. 现代医学, 2017, 45(3): 358-362.
22	Knudsen ST, Jeppesen P, Poulsen PL, et al. Plasma concentrations of osteoprotegerin during normo- and hyperglycaemic clamping [J]. Scand J Clin Lab Invest, 2007, 67(2): 135-142.
23	Suzuki K, Kurose T, Takizawa M, et al. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density [J]. Diabetes Res Clin Pract, 2005, 68(2): 117-125.

组别	例数	年龄（岁）	左股骨颈BMD	腰椎BMD
糖尿病组	64	65（52，89）	0.73（0.58，0.95）	0.74（0.61，0.95）
非糖尿病组	64	65（44，82）	0.71（0.56，0.94）	0.76（0.56，0.94）
Z值	?	0.322	0.841	0.779
P值	?	0.748	0.400	0.436

组别	例数	年龄（岁）	左股骨颈BMD	腰椎BMD
糖尿病组	64	65（52，89）	0.73（0.58，0.95）	0.74（0.61，0.95）
非糖尿病组	64	65（44，82）	0.71（0.56，0.94）	0.76（0.56，0.94）
Z值	?	0.322	0.841	0.779
P值	?	0.748	0.400	0.436

组别	例数	OPG（pg/ml）	TGF-β（ug/l）	IL-6（pg/ml）
糖尿病组	64	357.16（159.98，543.25）	40.35（23.51，66.25）	11.91（7.14，17.48）
非糖尿病组	64	337.33（168.42，537.51）	36.75（10.34，64.58）	10.00（5.26，18.34）
Z值	?	2.264	2.836	2.431
P值	?	0.024	0.005	0.015

组别	例数	OPG（pg/ml）	TGF-β（ug/l）	IL-6（pg/ml）
糖尿病组	64	357.16（159.98，543.25）	40.35（23.51，66.25）	11.91（7.14，17.48）
非糖尿病组	64	337.33（168.42，537.51）	36.75（10.34，64.58）	10.00（5.26，18.34）
Z值	?	2.264	2.836	2.431
P值	?	0.024	0.005	0.015

?	OPG		TGF-β		IL-6
?	相关系数	P值	相关系数	P值	相关系数	P值
FRAX主要骨质疏松性骨折	0.329	<0.001	0.427	<0.001	0.369	<0.001
FRAX髋部骨折	0.260	0.003	0.328	<0.001	0.394	<0.001

Please choose a citation manager

Content to export